Sign In
Buy LLY
$1,185.71
-6.23 (-0.523%)
At Close: Aug 07, 2026
Jim Cramer explains why he favors Eli Lilly in the weight loss drug space
07:48pm, Monday, 13'th Nov 2023
'Mad Money' host Jim Cramer compares the weight loss drug offerings from Novo Nordisk and Eli Lilly and talks what investors need to know about both companies.
Jim Cramer weighs the market impact of Eli Lilly and Novo Nordisk's weight loss drugs
07:47pm, Monday, 13'th Nov 2023
'Mad Money' host Jim Cramer compares the weight loss drug offerings from Novo Nordisk and Eli Lilly and talks what investors need to know about both companies.
Jim Cramer says insurance companies will pay for 'revolutionary' weight-loss drugs for their members
07:04pm, Monday, 13'th Nov 2023
CNBC's Jim Cramer on Monday emphasized his belief that companies making GLP-1 diabetes and obesity drugs will be valuable.
Eli Lilly rides on Novo's coattails as BofA analysts maintain ‘Buy' rating following SELECT trial data
01:42pm, Monday, 13'th Nov 2023
Novo Nordisk (NYSE:NVO) presented the full results from its SELECT cardiovascular trial at an American Heart Association (AHA) meeting on Saturday and analysts at Bank of America (BofA) Securities sai
Eli Lilly's experimental drug lowers risk of heart disease by 94%: study
01:42pm, Monday, 13'th Nov 2023
Pharmaceutical giant Eli Lilly's experimental vaccine-like drug slashed a risk factor for heart disease by a whopping 94% for almost a year, according to a report.
Eli Lilly's experimental heart drug cuts genetic risk factor by 94% for a year
11:42am, Monday, 13'th Nov 2023
Eli Lilly and Co (NYSE:LLY)'s experimental therapy lepodisiran reduced the harmful risk factor for lipoprotein (a) by up to 94% for up to a year with just a single dose, data from a first-in-human tri
Better Buy Now: Novo Nordisk vs. Eli Lilly
06:17am, Monday, 13'th Nov 2023
Novo Nordisk's weight management blockbuster produced some surprising results for its ability to reduce patients' risk of a second heart attack. The Food and Drug Administration recently approved Eli
Eli Lilly: Favorable Developments Continue Regarding Anti-Obesity Drug Franchise
03:22am, Monday, 13'th Nov 2023
Eli Lilly's anti-obesity drug Zepbound (tirzepatide) receives approval in the US and recommended approval in the EU. The SELECT study data shows that semaglutide 2.4 mg reduces major adverse cardiovas
Eli Lilly and Company (LLY) Presents at UBS Biopharma 2023 Conference (Transcript)
01:01pm, Saturday, 11'th Nov 2023
Eli Lilly and Company (NYSE:LLY ) UBS Biopharma 2023 Conference November 8, 2023 3:00 PM ET Company Participants Patrik Jonsson - President, Lilly Immunology Conference Call Participants Trung Huynh -
Cautious Investor? 2 Safe Stocks You Also Can Count on For Growth
05:00am, Saturday, 11'th Nov 2023
Eli Lilly just gained approval for a drug that could win big in the multibillion-dollar weight-loss market. Johnson & Johnson is focusing on its high-growth businesses after the recent spinoff of its
Eli Lilly's Tirzepatide approved in the EU days after US and UK approval
01:05pm, Friday, 10'th Nov 2023
Eli Lilly (LLY) stock price movement has experienced a whirlwind since Wednesday's approval of its diabetes medication, Tirzepatide, for chronic weight management in the United States and the United K
3 Stocks to Buy for Retirees Looking to Beat Inflation
12:20pm, Friday, 10'th Nov 2023
At 3.7%, inflation remains an issue. While consumer prices have come down from their peak of 9.1% in June 2022, the inflation rate in the U.S. remains well above the Federal Reserve's 2% annualized ta
Who's afraid of Ozempic? From restaurants to package makers, companies work to calm investors' GLP-1 jitters.
11:13am, Friday, 10'th Nov 2023
That's the message from many corporate executives who have lately been peppered with questions about how Wegovy, Ozempic and other drugs widely used for weight loss may impact their bottom line.
Where Will Eli Lilly Be in 5 Years?
10:23am, Friday, 10'th Nov 2023
Eli Lilly is pulling out all the stops to gain market share in a pair of key markets. It'll face stiff opposition from Novo Nordisk, among other contenders.
EU regulator backs Eli Lilly's Mounjaro for weight management
07:31am, Friday, 10'th Nov 2023
Europe's medicines regulator said on Friday its committee had recommended changing authorization terms for Eli Lilly's drug Mounjaro to include weight-management.
